SCHEMBL4054082

SCHEMBL4054082

CN(C)/C=C(\C(=O)c1ccco1)c1ccncn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
PTPN1 P18031 1/20 0.39
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TP53 P04637 3/20 0.36
TSHR P16473 2/20 0.36
CYP2C9 P11712 1/20 0.36
P2RX7 Q99572 1/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
ALDH1A1 P00352 3/20 0.35
PKM P14618 2/20 0.35
MAPT P10636 1/20 0.35
FAAH O00519 1/20 0.35
GAA P10253 1/20 0.34
CYP1A2 P05177 1/20 0.34
LMNA P02545 2/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054086 1.00 CES2 (0.41) CES2CES1PTPN1HTTNPSR1
SCHEMBL5240764 1.00 CES2 (0.41) CES2CES1PTPN1HTTNPSR1
SCHEMBL1554508 0.82 TP53 (0.48) CES2CES1PTPN1HTTNPSR1
SCHEMBL1554509 0.82 TP53 (0.48) CES2CES1PTPN1HTTNPSR1
SCHEMBL4053247 0.80 CES2 (0.39) CES2CES1PTPN1HTTNPSR1
SCHEMBL4053242 0.80 CES2 (0.39) CES2CES1PTPN1HTTNPSR1
SCHEMBL3063645 0.80 CES2 (0.58) CES2CES1PTPN1HTTNPSR1
SCHEMBL4051492 0.73 CES2 (0.44) CES2CES1P2RX7NPC1RAB9A
SCHEMBL4051496 0.73 CES2 (0.44) CES2CES1P2RX7NPC1RAB9A
SCHEMBL2051578 0.72 MAPT (0.43) HTTP2RX7ALDH1A1PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 CES2 2193/4885CES1 2162/4885PTPN1 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.